Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

CD38

CD38 (cluster of differentiation 38), also known as cyclic ADP ribose hydrolase is a glycoprotein found on the surface of many immune cells (white blood cells), including CD4+, CD8+, B lymphocytes and natural killer cells. CD38 also functions in cell adhesion, signal transduction and calcium signaling.

CD38 inhibitor 1
T149131700637-55-3
CD38 inhibitor 1 is a potent CD38 inhibitor that is effective against human CD38 (IC50 value is 7.3 nM) and mouse CD38 (IC50 value is 1.9 nM).
  • $51
In Stock
Size
QTY
Luteolinidin chloride
TN18951154-78-5
Luteolinidin chloride is a natural product. It is a potent CD38 inhibitor which can protect the heart against I R injury with preservation of eNOS function and prevention of endothelial dysfunction in vivo.
  • $72
In Stock
Size
QTY
TargetMol | Citations Cited
MK-0159
T619332641484-61-7
MK-0159 is an orally available, highly potent CD38 inhibitor with myocardial injury protection for the study of cardiac ischemia and reperfusion injury.
  • $76
In Stock
Size
QTY
RBN013209
T600992597933-17-8
RBN013209 is a potent CD38 inhibitor. RBN013209 is useful in the treatment of cancer.
  • $56
In Stock
Size
QTY
Mezagitamab
T770842227490-52-8
Mezagitamab (TAK-079) is a fully humanized IgG1λ monoclonal antibody against CD38 with high affinity for CD38-expressing cells (including plasma mother cells, plasma cells, and natural killer cells), which depletes CD38-expressing tumor cells through antibody- and complement-dependent cytotoxicity Mezagitamab may be used in the study of recurrent refractory multiple myeloma (RRMM), which is the most common form of cancer. multiple myeloma (RRMM) and primary thrombocytopenic purpura (ITP).
  • $197
In Stock
Size
QTY
Isatuximab
T389511461640-62-9
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38 in malignant cells of the hematological system, a highly expressed protein in multiple myeloma. It exhibits antitumor activity, antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cytophagocytosis, directly inducing apoptosis without crosslinking. Isatuximab inhibits CD38 extracellular enzyme activity, affecting various cellular functions.
  • $289
In Stock
Size
QTY
Erzotabart
T824402430792-01-9
Erzotabart, an IgG1-kappa monoclonal antibody targeting CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) in Homo sapiens, exhibits antineoplastic activity [1].
  • Inquiry Price
Size
QTY
CD38 inhibitor 3
T797322857868-82-5
CD38 Inhibitor 3 (compound 1), with an IC50 of 11 nM, is a potent agent that enhances mitochondrial biogenesis, diminishes lactate levels, and augments both NAD+ content and Nrf2 expression. In a Pus1 -/- mouse model of mitochondrial myopathy, it also elevates muscle function and bolstering exercise capacity [1].
  • $1,520
6-8 weeks
Size
QTY
Felzartamab
T770062197112-39-1
Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants.
  • $247
In Stock
Size
QTY